BioSpace News Archive

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that Mr. Eric Myung, CPA, CA, has taken on the role of CFO. Mr. Myung will assume his CFO role effective immediately.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced that the US Food and Drug Administration has accepted for filing the New Drug Application for the antibiotic ceftobiprole, which was submitted to the FDA on August 3rd this year.

Pneumagen announced positive results from its Phase 2, Proof of Concept, Controlled Human Infection Model study where patients were challenged with influenza virus following administration of Neumifil.

Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round.

Broken String Biosciences announced the expansion of its senior leadership team with the appointments of Vincent Smith, PhD, as Chief Technology Officer and Jessica Rich as VP Business Development.

Opthea Limited announced that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.

Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30.

Boston Scientific Corporation will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT.

DexCom, Inc. announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany.